Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab

BACKGROUND: Preliminary evidence indicates that early tumor shrinkage (ETS) following immune checkpoint inhibitor (ICI) initiation may be associated with survival outcomes in patients with advanced melanoma. ETS has not been explored as a biomarker of survival outcomes or patient-reported outcomes i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Ashley M, Kichenadasse, Ganessan, Karapetis, Chris S, Rowland, Andrew, Sorich, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279663/
https://www.ncbi.nlm.nih.gov/pubmed/32503948
http://dx.doi.org/10.1136/jitc-2019-000500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279663/
https://www.ncbi.nlm.nih.gov/pubmed/32503948
http://dx.doi.org/10.1136/jitc-2019-000500

Ejemplares similares